Eli Lilly (NYSE:LLY) shares are trading higher on Monday, after the company received FDA approval for Taltz for treatment of pediatric patients with moderate to severe plaque psoriasis.
Eli Lilly is a pharmaceutical company incorporated in 1901.
Eli Lilly shares were trading up 3.1% to $138.34 at time of publication. The stock has a 52-week high of $147.87 and a 52-week low of $101.36.
Related Links:
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted In:
